Ignite Creation Date:
2025-12-25 @ 2:24 AM
Ignite Modification Date:
2025-12-27 @ 4:47 AM
Study NCT ID:
NCT01642134
Status:
COMPLETED
Last Update Posted:
2019-08-09
First Post:
2012-06-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001024', 'term': 'Aortic Valve Stenosis'}, {'id': 'D020521', 'term': 'Stroke'}], 'ancestors': [{'id': 'D000082862', 'term': 'Aortic Valve Disease'}, {'id': 'D006349', 'term': 'Heart Valve Diseases'}, {'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D014694', 'term': 'Ventricular Outflow Obstruction'}, {'id': 'D002561', 'term': 'Cerebrovascular Disorders'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D001241', 'term': 'Aspirin'}, {'id': 'D000077144', 'term': 'Clopidogrel'}, {'id': 'D000074', 'term': 'Acenocoumarol'}], 'ancestors': [{'id': 'D012459', 'term': 'Salicylates'}, {'id': 'D062385', 'term': 'Hydroxybenzoates'}, {'id': 'D010636', 'term': 'Phenols'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D013988', 'term': 'Ticlopidine'}, {'id': 'D058924', 'term': 'Thienopyridines'}, {'id': 'D013876', 'term': 'Thiophenes'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D011725', 'term': 'Pyridines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D015110', 'term': '4-Hydroxycoumarins'}, {'id': 'D003374', 'term': 'Coumarins'}, {'id': 'D001578', 'term': 'Benzopyrans'}, {'id': 'D011714', 'term': 'Pyrans'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 124}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2013-04'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-08', 'completionDateStruct': {'date': '2019-06-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-08-08', 'studyFirstSubmitDate': '2012-06-19', 'studyFirstSubmitQcDate': '2012-07-12', 'lastUpdatePostDateStruct': {'date': '2019-08-09', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2012-07-17', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2019-06-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Evaluate the effectiveness of dual antiplatelet therapy versus oral anticoagulation for prevention of cerebral thromboembolism by the detection of new areas of cerebral infarction by Magnetic Resonance Imaging (MRI) 3 months after TAVI.', 'timeFrame': '3 months'}], 'secondaryOutcomes': [{'measure': 'Determine the incidence of new areas of cerebral infarction by MRI between the different routes of vascular access and the various valve devices.', 'timeFrame': '1 hour before TAVI, 1 hour and 24 hours after TAVI'}, {'measure': 'Identify the development of cognitive impairment after TAVI', 'timeFrame': 'Pre-TAVI, and at 1º 3º and 6º month after TAVI', 'description': 'By the application of: 1)Mini-Mental State Examination (MMSE); 2)SF 36 (spanish version); 3)The NIHSS (National Institute of Health Stroke Scale). The evaluation of the neurological tests will be performed by a certificated neurologist.'}, {'measure': 'Evaluate the Quality of life after TAVI.', 'timeFrame': 'Pre-TAVI, and at 1º; 3º and 6º month after TAVI.', 'description': 'By the application of Euroquol EQ5.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Antiplatelet', 'Anticoagulation'], 'conditions': ['Aortic Valve Stenosis', 'Stroke']}, 'referencesModule': {'references': [{'pmid': '21639811', 'type': 'BACKGROUND', 'citation': 'Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011 Jun 9;364(23):2187-98. doi: 10.1056/NEJMoa1103510. Epub 2011 Jun 5.'}, {'pmid': '20961243', 'type': 'BACKGROUND', 'citation': 'Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010 Oct 21;363(17):1597-607. doi: 10.1056/NEJMoa1008232. Epub 2010 Sep 22.'}, {'pmid': '20177005', 'type': 'BACKGROUND', 'citation': 'Kahlert P, Knipp SC, Schlamann M, Thielmann M, Al-Rashid F, Weber M, Johansson U, Wendt D, Jakob HG, Forsting M, Sack S, Erbel R, Eggebrecht H. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation. 2010 Feb 23;121(7):870-8. doi: 10.1161/CIRCULATIONAHA.109.855866.'}, {'pmid': '11062293', 'type': 'BACKGROUND', 'citation': 'Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ. Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke. 2000 Nov;31(11):2670-7. doi: 10.1161/01.str.31.11.2670.'}, {'pmid': '18375137', 'type': 'BACKGROUND', 'citation': 'Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U, Nashef SA; EACTS Audit and Guidelines Committee. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg. 2008 Jul;34(1):73-92. doi: 10.1016/j.ejcts.2008.02.024. Epub 2008 Mar 28.'}], 'seeAlsoLinks': [{'url': 'http://www.cardiologia-vigo.com/', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine the incidence of major vascular events (ischemic or haemorrhagics) at the third month after initiation of the antithrombotic treatment (oral anticoagulation or dual antiplatelet therapy) in both arms followed TAVI.', 'detailedDescription': 'Transcatheter aortic valve implantation (TAVI) procedure using any of their vascular access is an option with proven benefit definitively for treatment of severe symptomatic aortic stenosis in patients considered unsuitable for conventional open heart surgery.\n\nBy avoiding the hemodynamic effects, cardiovascular and cerebral microembolic load of cardiopulmonary bypass circulation, it is assumed that the TAVI procedure is beneficial despite the risk of neurological complications. Currently antithrombotic therapy after the procedure is not standardized. International treatment guidelines recommends that post-operative patients with a conventional surgical aortic bioprosthesis maintain oral anticoagulation for 3 months after the procedure, unless otherwise noted for its continuation. Whereas some studies have postulated that in patients with aortic bioprostheses, dual antiplatelet therapy is as effective to prevent major cardiac and cerebrovascular events as oral anticoagulation, with a lower incidence of bleeding complications at 3 months of treatment, the investigators formulated the following hypothesis:\n\n• There is a lower incidence of major cardiac and cerebrovascular events in patients with dual antiplatelet therapy compared to patients with oral anticoagulation for 3 months after implantation of an aortic bioprosthesis TAVI procedure.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Adult patients (more than 18 years) with ability to understand and accept the participation in the clinical trial.\n2. Patients with symptomatic degenerative severe aortic stenosis rejected for conventional surgical aortic valve replacement due to unacceptably high risk and accepted for TAVI procedure\n3. Signed informed consent.\n4. Patients who are not participating in any other clinical trial or research study.\n\nExclusion Criteria:\n\n1. Patients under oral anticoagulation treatment\n2. Patients who can not undergo MRI study\n3. Recent stroke \\< 14 days prior, revascularized coronary artery disease or life expectancy \\< 12 months\n4. Patients with proven allergy to aspirin, clopidogrel or acenocoumarol\n5. Patients that after TAVI procedure can not undergo a regimen of dual antiplatelet therapy or oral anticoagulation for 3 months due to any new post-TAVI medical indication'}, 'identificationModule': {'nctId': 'NCT01642134', 'acronym': 'AUREA', 'briefTitle': 'Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Hospital de Meixoeiro'}, 'officialTitle': 'PHASE IV Study of Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After Percutaneous Aortic Valve Implantation. Multicenter Randomized Clinical Trial', 'orgStudyIdInfo': {'id': 'MEIX-VALV-001'}, 'secondaryIdInfos': [{'id': '2011-005784-24', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Duoplavin', 'description': 'Both active substances in DuoPlavin: clopidogrel and acetylsalicylic acid, are inhibitors of platelet aggregation. Clopidogrel stops the platelets aggregating by blocking ADP. Acetylsalicylic acid the platelets aggregating by blocking the prostaglandin cyclo oxygenase.', 'interventionNames': ['Drug: aspirin+clopidogrel (Duoplavin)']}, {'type': 'SHAM_COMPARATOR', 'label': 'acenocumarol', 'interventionNames': ['Drug: aspirin+clopidogrel (Duoplavin)']}], 'interventions': [{'name': 'aspirin+clopidogrel (Duoplavin)', 'type': 'DRUG', 'otherNames': ['DUOPLAVIN (aspirin 100 mg + clopidogrel 75 mg).', 'SINTROM (ACENOCUMAROL).'], 'description': '100 mg aspirin ;75 mg clopidogrel 3º months', 'armGroupLabels': ['Duoplavin', 'acenocumarol']}]}, 'contactsLocationsModule': {'locations': [{'zip': '20014', 'city': 'San Sebastián', 'state': 'Guipúzcoa', 'country': 'Spain', 'facility': 'Policlínica de Guipuzcoa.SA', 'geoPoint': {'lat': 43.56667, 'lon': -5.9}}, {'zip': '36312', 'city': 'Vigo', 'state': 'Pontevedra', 'country': 'Spain', 'facility': 'Hospital Universitario Álvaro Cunqueiro', 'geoPoint': {'lat': 42.23282, 'lon': -8.72264}}, {'zip': '36201', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital clinico Universitario Bellvitge', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '36201', 'city': 'Málaga', 'country': 'Spain', 'facility': 'Hospital Clinico Universitario de Malaga', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}], 'overallOfficials': [{'name': 'Andres Iniguez Romo, MD;PHD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital Universitario Alvaro Cunqueiro'}, {'name': 'Victor A. Jimenez Diaz, MD;Msc', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital clinico universitario Vigo'}, {'name': 'Mariano Larman Tellechea, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Policlínica de Guipuzcoa SA San Sebastián'}, {'name': 'Pablo Juan Salvadores, Pharma,MPH', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Hospital Universitario Álvaro Cunqueiro'}, {'name': 'Jose M. Hernandez, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital Virgen de la Victoria'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Andres Iñiguez Romo, MD, PhD', 'class': 'OTHER_GOV'}, 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'MD; PHD', 'investigatorFullName': 'Andres Iñiguez Romo, MD, PhD', 'investigatorAffiliation': 'Hospital de Meixoeiro'}}}}